Rachel Vatnsdal

Is taking that fourth-quarter number and rolling it into next year a reasonable starting point? Or are there things that we should be thinking of?

are you embedding any budget flush assumptions into that fourth-quarter guide? Or would that be upside

Can you talk about your ability to pass on price in this environment given the dynamic environment that we're seeing in light of tariffs?

Can you walk us through, have you had any concrete conversations with customers regarding these capacity build outs? And how do we think about the timing

could you quantify for us what level of headline risk can be really embedded into not only the fiscal 2Q guide, but the full-year guide at this point?

Can you just walk us through how much of the EPS number in the fiscal 2Q number especially is impacted by that FX given how much rates have really moved

how are you thinking about the timing of recovery on bio-processing equipment given those dynamics

would you consider revisiting that endemic rate as we get towards your end? Would you potentially revisit it for a fifth time

did you see orders grow high-single digits again this quarter sequentially or was order growth slightly less

What types of products are you seeing the most weakness in in that research market

Can you walk us through are you expecting Danaher to be impacted this - by this at all

how should we think about the pace of recovery throughout the year on Bioprocessing

Can you bucket how much of the $150 million is offset by each of those drivers

Can you just walk us through do you think most of this customer caution in light of the macro environment is mainly going to impact the second quarter

Can you walk us through what are you assuming by segment for the first quarter including and excluding that shipping comp across segments

have you seen any impact regarding some of this equipment stimulus to date yet? And is anything embedded for stimulus within that full number

What are your expectations for NIH in regards to funding next year?

can you help unpack for us a little bit what is currently assumed in terms of dollar amounts for what's going to be pressuring the EU?

what are you hearing from customers and your consultants in D.C. regarding the funding outlook for NIH this year

can you walk us through how are you thinking about those 3 end markets as we look to this 3% to 6% framework over the next few years

could you break down for us what percent of that $500 million update was related to ENG versus the CRO

Can you walk us through your broad pricing assumptions, expectations for this year? How much do you really think you will be able to mitigate

can you walk us through what have you seen since the new administration turnover in terms of customers' behavior

can you walk us through some of the drivers of that beat? Did you guys see any budget flush trends in the quarter

recurring revenues were solid in the quarter, but that operating margin was a little bit lighter than what Street was expecting. So can you unpack some of the drivers